Publications by authors named "A Jary"
Article Synopsis
- - Kaposi's sarcoma-associated herpesvirus (KSHV) is linked to various diseases, and the currently used method for detecting antibodies, the indirect immunofluorescence assay (IFA), is lengthy and dependent on the tester's skill.
- - A study compared IFA with an enzyme-linked immunosorbent assay (ELISA) for accuracy in detecting KSHV antibodies, revealing that ELISA demonstrated better sensitivity (94%) and maintained high specificity (100%), outperforming IFA (79% sensitivity).
- - The study suggests ELISA is a more reliable alternative for diagnosing KSHV in patients, especially those with weakened immune systems or prior inconclusive IFA results, emphasizing the need for improved serological
Article Synopsis
- The study investigates the reemergence of Kaposi sarcoma (KS) in people living with HIV who are on antiretroviral therapy (ART), suggesting that age-related immune decline (immunosenescence) may play a role.
- Researchers compared data, including immune responses and viral factors, from both HIV KS patients and classic KS patients who are HIV-uninfected, while also including age-matched controls.
- Findings indicate that despite younger ages and favorable CD4 counts in HIV KS patients, their immune profiles are similar to those of older cKS patients, pointing towards the need for new strategies to prevent and treat KS in individuals receiving ART.
Purpose: This phase 1b/2 trial evaluated the efficacy and safety of capmatinib plus nazartinib in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC).
Methods: In phase 1b, patients with progression on first-/second-generation EGFR-TKIs received escalating doses of capmatinib 200-400 mg bid plus nazartinib 50-150 mg qd. Once the MTD/RP2D was declared, phase 2 commenced with patient enrollment into groups according to mutation status and prior lines of treatment: group 1 (fasted; EGFR-TKI resistant; 1-3 prior lines; EGFR; any T790M/MET); group 2 (fasted; EGFR-TKI naïve; 0-2 prior lines; de novo T790M+; any MET); group 3 (fasted; treatment-naïve; EGFR; T790M-; any MET); group 4 (with food; 0-2 prior lines; EGFR; any T790M/MET).
Background: Shallow whole genome sequencing (Shallow-seq) is used to determine the copy number aberrations (CNA) in tissue samples and circulating tumor DNA. However, costs of NGS and challenges of small biopsies ask for an alternative to the untargeted NGS approaches. The mFAST-SeqS approach, relying on LINE-1 repeat amplification, showed a good correlation with Shallow-seq to detect CNA in blood samples.
View Article and Find Full Text PDF